线粒体渗透性转变孔结构和功能的研究进展

非正常生理浓度的Ca^2 和氧化应激等刺激线粒体渗透性转变孔(mitochondria permeability transition pore,MPTP)开放,使线粒体形态功能发生改变,被释放的细胞色素c和凋亡诱导因子(apoptosisinducing factor,AIF)等参与到caspase信号通路中,诱导细胞发生凋亡。本文在MPTP的主要组成成分、两种不同的结构功能模型、抑制剂对MPTP的抑制机制和缺血,再灌注及缺血预适应对MPTP开放的影响等方面的研究进展作一综述。     

β-淀粉样肽的细胞内毒性与线粒体通透性转变孔道

β-淀粉样肽（amyloid—β peptide,Aβ）是阿尔采末病患者脑内老年斑的主要成分,具有很强的神经毒性。近年来,研究发现细胞内产生和聚集的Aβ可以通过多种途径发挥其神经毒性作用。利用离体线粒体模型发现,Aβ可以导致线粒体通透性转变孔道（mitochondrial permeability transition pore,MPTP）开放。MPTP开放会进一步加剧线粒体功能的损伤,并可导致细胞色素c和凋亡诱导因子释放,在线粒体介导的细胞死亡中具有重要作用。Aβ引起的MPTP开放可能是胞内Aβ导致神经元死亡的重要通路,研究Aβ对该孔道的影响将有助于阐明Aβ的毒性机理并以期找到减轻Aβ损伤的新策略。     

线粒体移植治疗心血管疾病研究进展

心血管疾病的发病率和死亡率逐年升高,且在世界范围内的疾病负担中占据首位。线粒体功能异常可引起细胞到组织的病变,多种心血管疾病被证实与线粒体功能障碍有关。线粒体移植(mitochondria transplantation, MTP)是一种新兴的治疗手段,用于治疗因线粒体功能障碍引起的组织损伤。经过十多年从基础实验到临床试验的发展,MTP在心血管疾病中的治疗作用逐渐被证实,并且备受关注。该文就MTP的研究基础及其在心血管疾病中的研究进展进行综述。     

线粒体-内质网结构偶联与细胞免疫功能障碍

线粒体-内质网结构偶联(mitochondria-associated endoplasmic reticulum membrane,MAM)是线粒体和内质网发生交互作用功能平台。研究发现有几十种蛋白质富集于两细胞器外膜之间,与钙信号传导、脂质代谢、内质网应激和细胞凋亡等密切相关,影响病生理状态下免疫细胞的增殖、活化和凋亡。细胞免疫功能障碍是严重创(烧)伤感染、脓毒症发病机制中的重要病生理过程,本文综述MAM功能异常研究进展及其在免疫细胞功能障碍中的意义。     

脓毒性脑病的神经化学机制研究进展

脓毒性脑病是一种脓毒症所引起的全身性炎症反应,在多器官功能障碍综合征患者中出现。脓毒性脑病与多种炎症因子及化学物质有关。这些炎症因子可在全身引起炎症反应,破坏血脑屏障并影响脑功能,引起突触传递及可塑性异常等神经系统相关的病症。文中对近年来脓毒性脑病发病过程中所涉及的神经递质失衡、突触传递异常及相关神经调节作用以及检测神经递质的量子点技术进行综述总结,旨在推进未来脓毒性脑病的研究。     

二氮嗪对大鼠供心心肌线粒体结构及通透性的影响

目的:探讨线粒体ATP敏感性钾离子通道(mitoKATPC)开放剂二氮嗪(DE)对离体大鼠供心长时程低温保存时线粒体超微结构及线粒体渗透性转换孔(MPTP)开放的影响。方法:利用Langendorff离体鼠心灌注法,观察供心在4℃含不同浓度DE(15、30、45μmol/L)的Celsior保存液中保存9h后,复灌期心脏作功量(RPP)变化情况。比色法测定MPTP开放情况;透射电子显微镜观察心肌细胞线粒体超微结构的变化。结果:①Celsior保存液中加入30μmol/L的DE对促进长时程低温保存后供心收缩功能的恢复、减轻心肌细胞线粒体超微结构损伤和抑制MPTP开放的作用最显著。②DE的上述作用可分别被mitoKATP特异性阻断剂5-羟基葵酸盐(5-HD)及MPTP开放剂苍术苷(Atr)所取消。结论:DE可通过抑制MPTP开放而减轻由长时程低温保存导致的大鼠供心心肌线粒体超微结构的损伤。     

线粒体移植在治疗线粒体缺陷疾病中的研究进展

线粒体是真核细胞中重要的细胞器,是高等生命体赖以生存的能量来源.线粒体异常可引起细胞甚至器官发生病变,越来越多的疾病被证实与线粒体功能障碍有关.线粒体移植是从患者正常组织分离线粒体然后注入线粒体损伤或缺失的部位,使损伤细胞得到救治、器官功能得以恢复的全新干预技术.线粒体移植作为一种新兴治疗方案在一些疾病干预的基础研究中崭露头角,尤其是在保护心脏缺血再灌注损伤领域已经发展到临床试验阶段.本文从线粒体起源出发,总结了仍处于实验阶段的几种线粒体移植方法,概述了线粒体移植在脑缺血引起神经元损伤保护领域、心肌缺血再灌注损伤保护领域和肿瘤治疗领域的研究进展,从分子层面探讨了线粒体损伤及线粒体移植修复的机理,并提出研发患者专属的"线粒体移植治疗生物制剂"的设想,旨在为线粒体缺陷有关疾病的治疗研究提供新的视角.     

线粒体功能障碍在糖尿病肾病进展的作用

糖尿病肾病是糖尿病微血管并发症之一,亦是引起终末期肾脏病的主要原因。目前各种临床治疗手段并没有阻止糖尿病肾病患者肾功能的进行性减退。因此,当务之急是进一步研究糖尿病肾病的发病机制,并从中寻找新的治疗靶点。大量研究结果显示线粒体功能障碍在糖尿病肾病的发生发展过程中具有重要作用。正常线粒体功能的维持依赖于多方面因素的共同参与,如线粒体质量控制机制、线粒体DNA等。这篇综述回顾了关于线粒体与糖尿病肾病相关文献,阐述线粒体功能障碍在糖尿病肾病进展中可能的作用。     

肥胖状态下脂肪组织线粒体功能紊乱与运动调控

线粒体在包括脂肪组织在内的新陈代谢器官中扮演重要角色。脂肪组织包括白色脂肪组织(white adipose tissue, WAT)和棕色脂肪组织(brown adipose tissue, BAT),这两种组织功能相反。白色脂肪组织储存多余的能量,棕色脂肪组织则通过线粒体进行非颤栗性产热来消耗能量。在受到寒冷时、β-肾上腺素能受体激动剂或运动刺激时,白色脂肪组织棕色化形成形态与功能类似棕色脂肪细胞的米色脂肪细胞。在脂肪细胞中,线粒体调节脂肪细胞分化、脂质稳态、支链氨基酸代谢、产热作用以及白色脂肪组织棕色化,因此高活性的线粒体对于脂肪细胞的功能至关重要。研究表明,脂肪组织线粒体功能障碍与肥胖和2型糖尿病等代谢性疾病高度相关。肥胖时线粒体功能紊乱,表现为线粒体生物合成和活性降低、活性氧产生过量以及自噬增加,从而对脂肪组织功能产生不利影响。因此,调节脂肪组织线粒体功能的干预措施将有助于治疗肥胖。研究发现,运动是预防和改善肥胖的重要方法,通过增加线粒体生物合成和活性,改善脂肪组织氧化应激并抑制自噬,从而促进机体代谢。本文深入探讨了脂肪组织线粒体的功能、线粒体紊乱的表现形式以及运动的调控效应,将加深对运动减肥的理解与认识,同时为肥胖症的治疗提供新的方向和思路。     

Respiratory chain inhibition: one more feature to propose MPTP intoxication as a Leigh syndrome model

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxicated mice have been widely used to model the loss of dopaminergic neurons. As this treatment leads to basal ganglia degeneration, it was proposed that MPTP mice could be used as a model of Leigh syndrome. However, this mitochondrial pathology is biochemically characterized by a respiratory chain dysfunction. To determine if MPTP can affect in vivo mitochondria function, we measured the activities of mitochondrial respiratory chain complexes in several tissues. Our results show that MPTP affects mainly mitochondrial respiratory chain complex IV, as found in Leigh Syndrome, confirming that acute MPTP intoxicated mice are a good model of Leigh Syndrome.     

Tetraphenylphosphonium-selective electrode as a tool for evaluating mitochondrial permeability transition pore function in isolated rat hepatocytes

The changes in mitochondrial membrane potential (Deltapsi(m)) were used as an indicator for evaluating the mitochondrial permeability transition pore (MPTP) function. We found that in situ mitochondria in digitonin-permeabilized hepatocytes were coupled and responded to the addition of substrates, inhibitors and uncouplers. Ca(2+)-induced Deltapsi(m) dissipation was caused by MPTP opening because this process was inhibited by cyclosporin A. MPTP opening was enhanced by the pro-oxidant tert-butyl hydroperoxide.     

TNF-alpha-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol

Mitochondria are indispensable for bioenergetics and for the regulation of physiological/signaling events in cellular life. Although TNF-alpha-induced oxidative stress and mitochondrial dysfunction are evident in several pathophysiological states, the molecular mechanisms coupled with impaired cardiac function and its potential reversal by drugs such as Tempol or apocyanin have not yet been explored. Here, we hypothesize that TNF-alpha-induced oxidative stress compromises cardiac function by altering the mitochondrial redox state and the membrane permeability transition pore (MPTP) opening, thereby causing mitochondrial dysfunction. We measured the redox states in the cytosol and mitochondria of the heart to understand the mechanisms related to the MPTP and the antioxidant defense system. Our studies demonstrate that TNF-alpha-induced oxidative stress alters redox homeostasis by impairing the MPTP proteins adenine nucleotide translocator and voltage-dependent anion channel, thereby resulting in the pore opening, causing uncontrolled transport of substances to alter mitochondrial pH, and subsequently leading to dysfunction of mitochondria and attenuated cardiac function. Interestingly, we show that the supplementation of Tempol along with TNF-alpha restores mitochondrial and cardiac function.     

The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis

Sepsis is characterised by a systemic dysregulated inflammatory response and oxidative stress, often leading to organ failure and death. Development of organ dysfunction associated with sepsis is now accepted to be due at least in part to oxidative damage to mitochondria. MitoQ is an antioxidant selectively targeted to mitochondria that protects mitochondria from oxidative damage and which has been shown to decrease mitochondrial damage in animal models of oxidative stress. We hypothesised that if oxidative damage to mitochondria does play a significant role in sepsis-induced organ failure, then MitoQ should modulate inflammatory responses, reduce mitochondrial oxidative damage, and thereby ameliorate organ damage. To assess this, we investigated the effects of MitoQ in vitro in an endothelial cell model of sepsis and in vivo in a rat model of sepsis. In vitro MitoQ decreased oxidative stress and protected mitochondria from damage as indicated by a lower rate of reactive oxygen species formation (P=0.01) and by maintenance of the mitochondrial membrane potential (P<0.005). MitoQ also suppressed proinflammatory cytokine release from the cells (P<0.05) while the production of the anti-inflammatory cytokine interleukin-10 was increased by MitoQ (P<0.001). In a lipopolysaccharide-peptidoglycan rat model of the organ dysfunction that occurs during sepsis, MitoQ treatment resulted in lower levels of biochemical markers of acute liver and renal dysfunction (P<0.05), and mitochondrial membrane potential was augmented (P<0.01) in most organs. These findings suggest that the use of mitochondria-targeted antioxidants such as MitoQ may be beneficial in sepsis.     

Improved mitochondrial function with diet-induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids

Mitochondria can depolarize and trigger cell death through the opening of the mitochondrial permeability transition pore (MPTP). We recently showed that an increase in the long chain n3 polyunsaturated fatty acids (PUFA) docosahexaenoic acid (DHA; 22:6n3) and depletion of the n6 PUFA arachidonic acid (ARA; 20:4n6) in mitochondrial membranes is associated with a greater Ca(2+) load required to induce MPTP opening. Here we manipulated mitochondrial phospholipid composition by supplementing the diet with DHA, ARA or combined DHA+ARA in rats for 10 weeks. There were no effects on cardiac function, or respiration of isolated mitochondria. Analysis of mitochondrial phospholipids showed DHA supplementation increased DHA and displaced ARA in mitochondrial membranes, while supplementation with ARA or DHA+ARA increased ARA and depleted linoleic acid (18:2n6). Phospholipid analysis revealed a similar pattern, particularly in cardiolipin. Tetralinoleoyl cardiolipin was depleted by 80% with ARA or DHA+ARA supplementation, with linoleic acid side chains replaced by ARA. Both the DHA and ARA groups had delayed Ca(2+)-induced MPTP opening, but the DHA+ARA group was similar to the control diet. In conclusion, alterations in mitochondria membrane phospholipid fatty acid composition caused by dietary DHA or ARA was associated with a greater cumulative Ca(2+) load required to induced MPTP opening. Further, high levels of tetralinoleoyl cardiolipin were not essential for normal mitochondrial function if replaced with very-long chain n3 or n6 PUFAs.     

Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A

Cyclosporin A (CsA) inhibits opening of the mitochondrial permeability transition pore (MPTP), a critical event in some forms of necrotic and apoptotic cell death, by binding to cyclophilin D (CyP-D) and inhibiting its peptidyl-prolyl cis-trans isomerase (PPIase) activity. Sanglifehrin A (SfA), like CsA, exerts its immunosuppressive action by binding to cyclophilin A but at a different site from CsA, and unlike the latter, SfA does not inhibit calcineurin activity. Here we demonstrate that SfA inhibits the PPIase activity of CyP-D (K(0.5) 2 nm) and acts as a potent inhibitor of MPTP opening under both energized and de-energized conditions. However, unlike CsA, the dose-response curve for inhibition by SfA is sigmoidal rather than hyperbolic, suggesting a multimeric structure for the MPTP with cooperativity between subunits. Furthermore, SfA does not prevent CyP-D binding to submitochondrial particles or detergent-solubilized adenine nucleotide translocase (ANT), implying that CyP-D binding to the ANT does not require PPIase activity but pore opening does. Once bound to the MPTP, SfA is not readily dissociated, and inhibition of pore opening is maintained following extensive washing. To investigate the potential of SfA as an inhibitor of cell death in vivo, we used the Langendorff perfused rat heart. SfA caused a time-dependent inhibition of the MPTP that was maintained on mitochondrial isolation to a greater extent than was CsA inhibition. We demonstrate that SfA, like CsA, improves the recovery of left ventricular developed pressure during reperfusion after 30 min of global ischemia and greatly reduces lactate dehydrogenase release, implying inhibition of necrotic damage. Because SfA does not inhibit calcineurin activity, our data suggest that it may be more desirable than CsA for protecting tissues recovering from ischemic episodes and for studying the role of the MPTP in cell death.     

Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure

Although sepsis is the major cause of mortality and morbidity in the critically ill, precise mechanism(s) causing multiorgan dysfunction remain unclear. Findings of impaired oxygen utilization in septic patients and animals implicate nitric oxide-mediated inhibition of the mitochondrial respiratory chain. We recently reported a relationship between skeletal muscle mitochondrial dysfunction, clinical severity, and poor outcome in patients with septic shock. We thus developed a long-term, fluid-resuscitated, fecal peritonitis model utilizing male Wistar rats that closely replicates human physiological, biochemical, and histological findings with a 40% mortality. As with humans, the severity of organ dysfunction and eventual poor outcome were associated with nitric oxide overproduction and increasing mitochondrial dysfunction (complex I inhibition and ATP depletion). This was seen in both vital (liver) and nonvital (skeletal muscle) organs. Likewise, histological evidence of cell death was lacking, suggesting the possibility of an adaptive programmed shutdown of cellular function. This study thus supports the hypothesis that multiorgan dysfunction induced by severe sepsis has a bioenergetic etiology. Despite the well-recognized limitations of laboratory models, we found clear parallels between this long-term model and human disease characteristics that will facilitate future translational research.     

The role of mitochondria in sepsis-induced cardiomyopathy

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Myocardial dysfunction, often termed sepsis-induced cardiomyopathy, is a frequent complication and is associated with worse outcomes. Numerous mechanisms contribute to sepsis-induced cardiomyopathy and a growing body of evidence suggests that bioenergetic and metabolic derangements play a central role in its development; however, there are significant discrepancies in the literature, perhaps reflecting variability in the experimental models employed or in the host response to sepsis. The condition is characterised by lack of significant cell death, normal tissue oxygen levels and, in survivors, reversibility of organ dysfunction. The functional changes observed in cardiac tissue may represent an adaptive response to prolonged stress that limits cell death, improving the potential for recovery. In this review, we describe our current understanding of the pathophysiology underlying myocardial dysfunction in sepsis, with a focus on disrupted mitochondrial processes.     

The influence of ATP-dependent K(+)-channel diazoxide opener on the opening of mitochondrial permeability transition pore in rat liver mitochondria

The influence of mitochondrial ATP-dependent K(+)-channel (K+(ATP)-channel) opener, diazoxide (DZ) on the mitochondrial permeability transition pore (MPTP) opening in rat liver mitochondria is studied. In the absence of DZ the MPTP opening leads to the increase in the rate of K(+)- and Ca(2+)-cycling supported by the simultaneous functioning of K(+)-channels and K+/H(+)-antiporter, and also Ca(2+)-uniporter together with MPTP as the cations influx and efflux pathways. Independent of MPTP opening, the activation of both constitutes of K(+)-cycle, K(+)-uptake as well as K+/H(+)-exchange, by DZ is observed. It is shown that the activation of transmembrane exchange of K+, combined with MPTP opening, results in partial inhibition of the latter. A simple methodical approach for the estimation of DZ influence on the open state of mitochondrial pore is proposed. It is shown that MPTP closure followed by Ca2+ reentry to the matrix is accompanied by the K+/H(+)-exchange inhibition which takes place in the same timeframes as the increase in matrix Ca2+ content. Relevant to physiological conditions, an important physiological function of MPTP is revealed, that is the maintenance of relatively low matrix level of Ca2+ accompanied by the acceleration of transmembrane ion exchange (K+ and Ca2+) which could strongly influence the energy state and energy-dependent processes in mitochondria.     

Minocycline,levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease

Mitochondrial dysfunction is the foremost perpetrator of the nigrostriatal dopaminergic neurodegeneration leading to Parkinson's disease (PD). However, the roles played by majority of the mitochondrial proteins in PD pathogenesis have not yet been deciphered. The present study investigated the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and combined maneb and paraquat on the mitochondrial proteome of the nigrostriatal tissues in the presence or absence of minocycline, levodopa and manganese (III) tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP). The differentially expressed proteins were identified and proteome profiles were correlated with the pathological and biochemical anomalies induced by MPTP and maneb and paraquat. MPTP altered the expression of twelve while combined maneb and paraquat altered the expression of fourteen proteins. Minocycline, levodopa and MnTMPyP, respectively, restored the expression of three, seven and eight proteins in MPTP and seven, eight and eight proteins in maneb- and paraquat-treated groups. Although levodopa and MnTMPyP rescued from MPTP- and maneb- and paraquat-mediated increase in the microglial activation and decrease in manganese-superoxide dismutase expression and complex I activity, dopamine content and number of dopaminergic neurons, minocycline defended mainly against maneb- and paraquat-mediated alterations. The results demonstrate that MPTP and combined maneb and paraquat induce mitochondrial dysfunction and microglial activation and alter the expression of a bunch of mitochondrial proteins leading to the nigrostriatal dopaminergic neurodegeneration and minocycline, levodopa or MnTMPyP variably offset scores of such changes.